3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
OTHER_GOV
1
OTHER
1
NIH
1
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
15
Endocrine
15
Thoracic
10
Gastrointestinal
10
CNS
7
Dermatologic
6
Breast
6
Genitourinary
5
Sarcoma
4
Gynecologic
4
NET
3
Lymphoid
2
Other solid neoplasm
1
Conditions
Lymphoma, Non-Hodgkin
767
Lymphoma
713
Leukemia, Lymphocytic, Chronic, B-Cell
560
Lymphoma, Follicular
515
Lymphoma, Large B-Cell, Diffuse
440
Precursor Cell Lymphoblastic Leukemia-Lymphoma
331
Recurrence
317
Lymphoma, B-Cell
294
Neoplasms
261
Lymphoma, Mantle-Cell
251
Leukemia
231
Multiple Myeloma
189
Hodgkin Disease
179
Leukemia, Myeloid, Acute
178
Lymphoma, B-Cell, Marginal Zone
135
Lymphoma, T-Cell, Peripheral
119
Burkitt Lymphoma
105
Myelodysplastic Syndromes
101
Hematologic Neoplasms
100
Lymphoma, T-Cell, Cutaneous
88
Waldenstrom Macroglobulinemia
84
Leukemia, B-Cell
79
Lymphoma, T-Cell
74
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
65
Lymphoproliferative Disorders
57
Hematologic Diseases
57
Melanoma
54
Carcinoma, Non-Small-Cell Lung
54
Breast Neoplasms
51
Mycosis Fungoides
49
Interventions
entrectinib
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Thyroid Cancer, Papillary
×
Lymphoid
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts